Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compound Kushen Injection Combined With Pembrolizumab for Cervical Adenocarcinoma
NCT05259540Phase 2Not yet recruiting
- Sponsor
- Women's Hospital, Zhejiang University School of Medicine
- Start
- Jan 2023
- Primary completion
- Dec 2025
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of compound kushen injection, pembrolizumab in cervical adenocarcinoma, sponsored by Women's Hospital, Zhejiang University School of Medicine. Planned start Jan 2023; status: not yet recruiting.
02
Drugs
compound kushen injectionpembrolizumab
03
Conditions
cervical adenocarcinoma
Beyond the preview
Go deeper on NCT05259540.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05259540.